IgG4-related disease is a recently discovered pathological entity, histologically characterised by fibrosis and IgG4-positive plasma cell infiltration. This condition may virtually involve every site of the organism, with a various range of clinical presentations. The most commonly affected organ is the pancreatic gland, but it can also involve the biliary tract, salivary and lacrimal glands, kidneys, orbital tissues, lymph nodes, lungs and many others. More recently, IgG4-related disease has been demonstrated to involve, in rare cases, also the central nervous system, with a pattern mainly characterised by hypertrophic pachymeningitis. In this paper we evaluated the clinical and magnetic resonance imaging features of the IgG4-related disease in the central nervous system, reporting a case of brain and spinal cord involvement. In our case, in fact, a 62-year-old man complaining of paresthesia, burning dysesthesia and severe hyposthenia in the lower limbs presented with inflammatory pseudotumour with orbital involvement and focal dural and spinal root thickening.
Introduction
Paraparesis refers to the partial loss of voluntary motor function, bilaterally involving the upper or, more frequently, lower limbs, sometimes associated with loss of sphincter control. This condition can be caused by a huge variety of pathological entities, thus diagnostic imaging is often necessary to detect a possible myelopathy.
IgG4-related disease is a systemic, often misdiagnosed, disease representing a very rare cause of progressing paraparesis. IgG4 is a subclass of IgG that accounts for less than 6% of total IgG in healthy adult subjects (8-140 mg/dL).
1 IgG4-related disease is an uncommon autoimmune condition characterised by increased serum IgG4 levels (>135 mg/dL), inflammatory lesions with IgG4-positive plasma cell infiltration, fibrosis and obliterative phlebitis. 2 The fibrosis associated with IgG4-related disease has a characteristic 'storiform' pattern, typified by a cartwheel appearance of the arranged fibroblasts and inflammatory cells. The presence of high serum level of IgG4 is common, but about 40% of patients with a histopathological diagnosis of IgG4-related disease have normal IgG4 serum levels. 3 Middle-aged men (more than 45 years old) are most commonly affected, with a male-female ratio of 3.7:1. 4 The infiltration of inflammatory cells causes massforming lesions and/or diffuse swelling of the involved organs, causing them to dysfunction. The disease was first described as an autoimmune pancreatic sclerosis with progressive changes in the gland architecture; however, about 20% of patients also present with retroperitoneal fibrous masses resulting in hydronephrosis, hydroureter and aortic dilatation. 5 Some patients with autoimmune pancreatitis also present with liver, renal, lacrimal and salivary gland involvement. 6 The clinical presentation depends on the site where the infiltration occurs; systemic symptoms such as fatigue or fever being quite uncommon; patients may also be asymptomatic. Involvement of the head and neck is relatively uncommon and it may occur in association with autoimmune pancreatitis or, more rarely, isolated.
Up to 26% of patients with IgG4-related disease present with involvement of the salivary and lacrimal glands, characterised by bilateral and painless enlargement of the glands or chronic sclerosing sialadenitis of submandibular glands. Bilateral swelling of the lacrimal and salivary glands was previously known as Mikulicz disease, an idiopathic condition, now considered as part of the spectrum of IgG4-related disease.
IgG4-related ophthalmic disease is the fifth most frequent extrapancreatic manifestation of IgG4-related disease with a prevalence of up to 12% of all cases. The first suspicion of orbital locations as part of the spectrum of IgG4-related disease was reported in Japan at the end of 2009. The most common features in IgG4-related ophthalmic disease are orbital mass lesions and ocular adnexal swelling. Structures involved by this disease include the lacrimal gland (62-88% of cases), orbital fat (29-40%) and the trigeminal nerve (10-39%). 7 A substantial proportion of idiopathic orbital inflammations, usually called orbital pseudotumous, represents a manifestation of IgG4-related disease. Clinically, these lesions are unilateral or bilateral masses, usually painless, which can affect the extrinsic or intrinsic ocular muscles as well as optic nerves or ocular branches of the trigeminal nerves.
Central or peripheral nervous system involvement, above all if isolated, is extremely rare and is usually characterised by pituitary enlargement 8 and a form of hypertrophic pachymeningitis. 9 Cerebrospinal fluid studies usually demonstrate a lymphocytic pleocytosis; in 50% of cases an elevated count of protein is present.
Finally, a clinical case of inflammatory pseudotumour as a tumefactive lesion involving the brain parenchyma has been reported in the literature in 2015. 10 The intraparenchymal brain involvement of IgG4-related disease should therefore be considered as exceptional.
We report an uncommon clinical case of IgG4-related inflammatory pseudotumour with orbital involvement associated with hypertrophic pachymeningitis and enlargement of the spinal roots, causing visual impairment and progressive paraparesis in a previously healthy middle-aged man.
Case report
This study was carried out according to the Declaration of Helsinki principles and approved by our institutional review board. The patient gave informed consent to publish this work and to report individual data.
A 62-year-old man, recently admitted to the neurological department of our hospital, arrived in our department on January 2016 to have a magnetic resonance imaging (MRI) follow-up examination after recent surgical resection of a solid formation involving the right eye. During the collection of the medical history, the patient referred to the comparison since November 2011 of retrobulbar headaches, loss of visual acuity and diplopia in the right eye associated with ipsilateral ptosis and mild dysesthesia of the right cheek.
He had a brain MRI examination in 2012 in another hospital where a solid tissue involving right cavernous sinus was observed. This lesion was considered to be an optic cavernous sinus meningioma and the patient was treated for this condition in 2012 and 2013 with targeted radiotherapy. He then had subsequent brain MRI follow-up examinations, the last one in November 2015, confirming the presence of a solid formation in the right middle cranial fossa, extending from the cavernous sinus to the right eye socket, closely adjacent to the extrinsic orbital muscles and the ipsilateral optic nerve. This lesion, measuring about 4 cm anterior to posterior, appeared inhomogeneously hypointense in fluid-attenuated inversion recovery (FLAIR), T1-and T2-weighted sequences ( Figure 1) ; after intravenous administration of contrast medium, the lesion showed intense and mildly inhomogeneous enhancement ( Figure 2 ).
Considering the slightly progressive increase in the dimensions of the orbital lesion and the lack of clinical improvement after radiotherapy, the patient underwent surgery on 21 January 2016, with partial resection of the mass and right eye enucleation.
The histopathological analysis revealed marked proliferation of fibroblastic-like cells and mononuclear cell infiltration, predominantly plasma cells; these features were consistent with IgG4-related sclerosing inflammatory pseudotumour (Figure 3) .
For 3 months the patient had been complaining of paresthesia, burning dysesthesia, severe hyposthenia and severe muscular atrophy of both lower limbs, particularly on the right side. These symptoms had recently worsened, preventing him from walking and forcing him to use a wheelchair. MRI examination of the brain and spine was then requested to confirm a clinical suspicion of subacute myelopathy. Neurological examination during hospitalisation showed:
. proptosis and marked conjunctival chemosis of the right eye, with complete ophthalmoplegia; . right hemifacial hyposthesia; . peripheral deficit of VII right cranial nerve;
. severe weakness of lower limbs with some effort against gravity;
. hypotrophy and hypotony of the lower limbs, with muscle fasciculation; . tactile superficial hyposthesia and burning dysesthesia in the lower limbs; . muscular ache of the femoral quadriceps, right gastrocnemius and posterior muscles of the thighs; . hypo-elicitable reflexes in the lower limbs; . positive Babinsky sign; . chronic urinary retention.
Sensitive and motor-evoked potentials of the tibial and median nerves were performed, showing elongated latency and pyramidal suffering of the lower limbs.
MRI post-surgical examination of the brain and spine was performed in our department with 3 T Signa Excite (GE Healthcare Technology, Milwaukee, WI, USA), with the following sequences: axial BRAVO T1, axial T2 FSE, axial T2 FLAIR fat sat, coronal T2 TSE, axial DWI b1000 and apparent diffusion coefficient map. After intravenous administration of the contrast agent a three-dimensional T1 FSPGR sequence was performed. The MRI examination was extended to the spinal cord because of his lower limb clinical disorders. The sequences performed were: sagittal T2 FSE, sagittal T1 FSE, axial T2 FSE and, after injection of contrast agent, sagittal T1 FSE fat sat.
Brain MRI showed partial enucleation of the right eye (Figure 4(a) ). The analysis of the spine showed a focal altered signal intensity area affecting the spinal cord in the C4-D1 tract; this lesion was hypointense on T1-weighted sequences and hyperintense on T2-weighted sequences. Moreover, swelling of the medullary conus was also noted.
After intravenous administration of a gadolinium contrast agent, a diffuse and mildly inhomogeneous enhancement in the right eye socket, extending to the ipsilateral cavernous sinus, was observed (Figure 4(b) ).
Regarding the spine, T2-weighted sequences showed some altered signal intensity areas with focal swelling involving the spinal cord at the C4 level (anterior aspect of the spinal canal), C6-D1 tract (posterior aspect of the spinal canal) and the anterior aspect of the medullary conus ( Figure 5 ).
Post-contrast sequences highlighted some focal pachymeningeal enhancement at the aforementioned levels and evident caudal nerve root enhancement ( Figure 6 ).
During the hospital stay a lumbar puncture was also performed, revealing normal cell count values, a fair number of erythrocytes, rare lymphocytes and polymorphonuclear leucocytes, high protein levels (162 mg/dL) and the presence of oligoclonal bands. The haematochemical values showed an increase in Five days after the MRI examination, patient was discharged and treated with oral corticosteroid therapy (25 mg bid). As he was unresponsive to corticosteroids, he was given immunosuppressive therapy (rituximab 1 g iv every 15 days for a total of two doses). The patient is currently in follow-up.
Discussion
IgG4-related disease is an uncommon systemic fibroinflammatory condition, recently discovered and still unknown in many aspects. It is characterised by focal inflammation with a tendency towards hypertrophy and mass effect, consistent with the propensity of this disease to form mass lesions. IgG4 disease was first recognised by Hamano et al. 11 in 2001, as a form of chronic pancreatitis. Central nervous system manifestations were first described as hypophysitis and some cases of IgG4-related hypertrophic pachymeningitis. The first reports of orbital locations of this disease were reported in Japan at the end of 2009.
In the nervous system, most frequently the disease involves the lacrimal and salivary glands, but it may also present as an IgG4-related orbital inflammatory pseudo-tumour or IgG4-related orbital myositis.
Idiopathic hypertrophic cranial or spinal pachymeningitis is a diagnosis of exclusion, and a dural biopsy is essential to exclude possible known causes such as infectious, neoplastic, or autoimmune disorders. It is now accepted that a consistent proportion of cases previously considered 'orbital pseudo-tumour' or 'idiopathic hypertrophic pachymengitis' belong to the spectrum of IgG4-related disease, a systemic disease showing different epidemiological and histological patterns depending on the involved organ.
IgG4-related pancreatitis, in fact, shows a strong predilection for men, while IgG4-related ophthalmic disease affects men and women equally. Moreover, the orbital fibrosis usually shows a collagenous nature; pancreatic fibrosis, on the contrary, presents, as mentioned above, a 'storiform' pattern. It is important to highlight that IgG4-related ophthalmic disease appears to present an association with an increased risk of developing mucosa-associated lymphoid tissue lymphoma. The pathogenesis of IgG4-related pachymeningitis is still unknown but a specific response against an unknown antigen is strongly suspected. [11] [12] [13] [14] There are no definite diagnostic criteria for IgG4-related disease; however, Umehara et al. in 2011 1, 5 Figure 6. Focal pachymeningeal enhancements are evident in the cervical, dorsal spine and in the medullary conus, together with thickening of some nerve roots. proposed some diagnostic criteria (Table 1) . Some researchers recommend a cut-off level for the absolute number of IgG4-positive cells at greater than 50 per high power field, and a ratio of IgG4-positive cells/ IgG-positive cells of more than 40%. 5 IgG4 serum levels are not essential for the diagnosis, because the serum IgG4 level often correlates with the disease activity and it may be normal.
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Diagnostic imaging, together with clinical, laboratory and histopathological data, provides a fundamental diagnostic tool in the diagnosis of this entity. Computed tomography usually represents a first-step technique that can demonstrate, in the case of an orbital pseudo-tumour, a soft-tissue attenuation with evident enhancement, usually involving intra and extra-conal structures.
MRI is essential in this disease, as it may show focal inflammation with a tendency to produce masses and, in the case of spinal involvement, focal or diffuse meningeal thickening. MRI, in particular, can adequately demonstrate the presence of a low to intermediate signal intensity tissue in T1-and T2-weighted sequences, showing avid enhancement. The tissue is typically not destructive, showing a tendency to local infiltration and to encase surrounding structures. Focal pachymeningitis is characterised by broad-based meningeal thickening, showing a low to intermediate signal in T1-and T2-weighted sequences and avid, homogeneous enhancement after the administration of gadolinium.
Diffusion-weighted imaging in some cases demonstrates hyperintensity of the lesion as for an important fibrotic component.
Finally, 18 F-FDG positron emission tomographycomputed tomography has recently been shown to play an important role in the management of this disease, allowing the disclosure of other possible unknown sites of involvement, targeting access sites for biopsies and above all monitoring the metabolic activity of the disease and treatment response.
The long-term prognosis of this entity still remains controversial as no long-term follow-up studies are available. Parney et al. 16 reported the outcomes of 33 patients with idiopathic hypertrophic cranial or spinal pachymeningitis. According to their article 26% experienced full remission without steroid dependence, 15% experienced steroid-dependent partial or complete remission, 15% experienced a progressive course despite steroid therapy and 32% died regardless of treatment.
It is difficult to evaluate the therapy tendency because the disease is rare and recently diagnosed, so there is no unified treatment protocol. The first-line treatment currently consists of steroid therapy. Although corticosteroids have proved to be effective in the early stages of the disease, their effect is rarely durable and most of patients experience recurrences of symptoms. Rituximab is the second-line treatment and is used in patients who do not respond to prednisone and in patients who have strong relative contraindications to glucocorticoid therapy. The most used dosage reported in the literature is 1 g every 15 days for a total of two doses. 17 In addition, immunosuppressant agents such as azathioprine, mycophenolate mofetil and methotrexate are frequently used as glucocorticoid-sparing agents or remission maintenance drugs after glucocorticoidinduced remissions. In our case a combination of a glucocorticoid agent and rituximab (immunomodulant agent) was used.
Our case highlights that a full awareness and prompt diagnosis of this pathological entity is essential to avoid misdiagnosis, therapeutic delays and unnecessary invasive procedures in a systemic disease that still represents a diagnostic challenge.
Funding

